Cancer News: Prostate
Researchers shift focus to prostate tumor genomic analysis to identify the best treatment among radiation, surgery, or other therapy.
Some of the latest prostate cancer drugs target a type of cells which may not be driving the tumor's growth, as previously thought.
3D mapping biopsies for prostate cancer were found more effective in location tumors, and a new study reports the locations that ultrasound-guided biopsies miss.
A US hospital has began treatments to prostate cancer patients whose tumor has spread to the bones, using a recently approved radioactive agent called Xofigo.
A possible explanation for relapse after hormone therapy for prostate cancer was provided by genes. This may lead to more tailored treatment for some patients.
99% of men after receiving proton therapy for early- and intermediate-risk prostate cancer have no evidence of disease and enjoy excellent quality of life. 76% with high-risk enjoy the same benefits.
Gene mutations in men with family history of prostate cancer can identify those at high risk. This discovery can lead to active monitoring for early detection.
Genetic screening of men with a family history of prostate cancer can identify those at high risk of aggressive forms of the disease, and suggest monitoring.
Sedentary behavior (ie without significant physical activity) does not clearly increase prostate cancer risk, based on a large scale analysis of 170,481 men.
Higher radiotherapy doses reduced the need for follow-up hormone-deprivation therapy for localized prostate cancer patients, in 10 year results of a phase 3 trial. The trial was the largest one of its kind.
Levels of a substance called “Bisphenol A” (BPA) in men’s urine could be a marker of prostate cancer. BPA is a common pollutant with estrogen activity.
A new study focusing on prostate cancer showed that younger patients who undergo surgery have lower mortality rates compared to those who choose not to.
A new licensing agreement will bring to the market a new test for early detection of prostate and bladder cancers. The test is based on the EN2 biomarker.
Prostatectomy is better for patients with early stage prostate cancer, compared to “watchful waiting”. This topic still attracts much debate among researchers.
Prostate cancer mortality is 20% lower in areas with frequent use of PSA testing, compared with areas with little testing, according to a study.
Stereotactic radiotherapy for treating prostate cancer, although faster and less expensive than standard radiotherapy, may cause more urinary complications.
Early stage prostate cancer patients who received androgen deprivation as their primary treatment instead of surgery or radiation, did not get any benefit.
Permanent brachytherapy (a procedure placing radioactive sources inside the prostate) preserves erectile function in almost 50% of prostate cancer patients.
A new, patient-friendly examination for prostate cancer has been developed. It drastically reduces the need for biopsies, while also being less costly.
Researchers claim to have created a test which can predict whether a man is at high risk of prostate cancer recurrence. The basis is men's genetic signature.
Patients with prostate cancer confined to the gland, but at risk of growing and spreading, benefit by radiotherapy combined with androgen deprivation therapy.
Half of 415 prostate cancer cases, classified as "slow growing" before surgery via grading and staging, were found to be more aggressive post-operation.
A man’s blood type may affect risk of prostate cancer recurrence after surgery. Specifically, patients with blood type "O" had a significantly decreased risk.
Vitamin D levels has been tied to a number of health aspects. A new study suggests that low vitamin D levels can predict aggressive prostate cancer risk.
Low testosterone levels in low-risk prostate cancer patients may indicate worsening of their disease, leading doctors to prescribe more aggressive treatment.
Minimally invasive robot-assisted radical prostatectomy (RARP) is as safe as open surgery for patients over age 65, but it is more expensive.
A diet rich in complex carbohydrates and fiber was associated with lower prostate cancer risk, according to an analysis of medical records showed.
Men who received radiation therapy for prostate cancer were more likely to develop bladder or rectal cancer, compared to those patients treated otherwise.
Overall survival for metastatic prostate cancer patients improved by more than a year when they received docetaxel at the start of androgen deprivation therapy.
A phase 3 study shows that adding the chemotherapy drug docetaxel to standard hormone therapy extends survival for men with prostate cancer by about 10 months.